Bibliography
Found 67 results
Filters: Author is Ellis, Ronald J and Keyword is Female [Clear All Filters]
.
Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era. J Infect Dis. 2016 ;213(7):1065-73.
Antiretroviral therapy reduces neurodegeneration in HIV infection. AIDS. 2015 ;29(3):323-30.
. Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. J Neurovirol. 2013 ;19(2):150-6.
A battery approach for measuring neuropsychological change. Archives of Clinical Neuropsychology: The Official Journal of the National Academy of Neuropsychologists [Internet]. 2006 ;21(1):83-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16169705
. Better executive function is independently associated with full HIV suppression during combination therapy. AIDS. 2019 ;33(15):2309-2316.
. Cannabis Exposure is Associated With a Lower Likelihood of Neurocognitive Impairment in People Living With HIV. J Acquir Immune Defic Syndr. 2020 ;83(1):56-64.
. Catechol-O-methyltransferase polymorphism Val158Met is associated with distal neuropathic pain in HIV-associated sensory neuropathy. AIDS. 2019 ;33(10):1575-1582.
. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011 ;25(14):1747-51.
Cerebrospinal fluid (CSF) biomarkers of iron status are associated with CSF viral load, antiretroviral therapy, and demographic factors in HIV-infected adults. Fluids Barriers CNS. 2017 ;14(1):11.
Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects. AIDS. 2019 ;33(3):475-481.
Chronic Distal Sensory Polyneuropathy Is a Major Contributor to Balance Disturbances in Persons Living With HIV. J Acquir Immune Defic Syndr. 2019 ;80(5):568-573.
. Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol. 2011 ;17(3):248-57.
The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk. Psychiatry Res. 2014 ;218(1-2):201-8.
. Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort. J Acquir Immune Defic Syndr. 2013 ;62(1):36-42.
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol. 2010 ;67(5):552-8.
Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study. Lancet HIV. 2019 ;6(7):e456-e462.
Effects of comorbidity burden and age on brain integrity in HIV. AIDS. 2019 ;33(7):1175-1185.
Effects of traumatic brain injury on cognitive functioning and cerebral metabolites in HIV-infected individuals. J Clin Exp Neuropsychol. 2011 ;33(3):326-34.
Etravirine in CSF is highly protein bound. J Antimicrob Chemother. 2013 ;68(5):1161-8.
Evaluation of Archival HIV DNA in Brain and Lymphoid Tissues. J Virol. 2023 ;97(6):e0054323.
Frailty in medically complex individuals with chronic HIV. AIDS. 2019 ;33(10):1603-1611.
Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. J Neurovirol. 2012 ;18(2):81-90.
Genetic variation in iron metabolism is associated with neuropathic pain and pain severity in HIV-infected patients on antiretroviral therapy. PLoS One. 2014 ;9(8):e103123.
Genome-wide association study of HIV-associated neurocognitive disorder (HAND): A CHARTER group study. Am J Med Genet B Neuropsychiatr Genet. 2017 ;174(4):413-426.